VIDAS TB-IGRA accuracy in tuberculosis patients and persons at varying risk of exposure
Delia Goletti,Niaz Banaei,Rahul Batra,Anne Emmanuelle Berger,Azra Blazevic,Elisabeth Botelho-Nevers,Ronan Breen,Natalie Bruiners,Emmanuelle Cambau,Etienne Carbonnelle,Charles L. Daley,Cécile Descotes-Genon,Francesco Di Gennaro,Florence Doucet-Populaire,Aliasgar Esmail,Julia Dolores Estrada Guzman,Luc Fontana,Maria Laura Gennaro,Deborah Handler,Rosa María Herrera Torres,Daniel Hoft,Nahed Ismail,Margaux Isnard,Alfred Lardizabal,François Xavier Lesage,Amanda Lopes,Williams Luciano López Vidal,Rene Machado Contreras,Philippe Manivet,Hubert Marotte,Frédéric Méchaï,Amel Medjahed-Artebasse,Richard Meldau,Yves Mérieux,Jacques Morel,Faiza Mougari,Suzette Oelofse,Fabrizio Palmieri,Jean Luc Perrot,Elisa Petruccioli,David T. Pride,Edouard Tuaillon,Caryn Upton,Naadira Vanker,Keertan Dheda
DOI: https://doi.org/10.1101/2024.07.03.24309158
2024-07-05
Abstract:Background: Detection and treatment of individuals with presumed latent tuberculosis (TB) infection (i.e., excluding active disease; LTBI) is imperative to achieve global TB control, as they represent a potential transmission reservoir. However, more sensitive and user–friendly diagnostic tools are needed.
Methods: We evaluated the accuracy for TB infection detection of the new VIDAS TB–IGRA (bioMérieux), a fully automated, single tube (thus eliminating the need for batch testing) overnight incubation assay, compared to the QuantiFERON –TB Gold Plus (QFT–Plus, QIAGEN), in a global multi–centre cross–sectional study ( ) that included patients with TB disease (n=200) or participants at varying levels of TB exposure (n=1460; mixed exposure–risk–population).
Results: VIDAS TB–IGRA identified TB disease with greater sensitivity than QFT–Plus (97.5% vs. 80.7%, P<0.01%), and yielding significantly fewer false–negatives (2.5% vs. 17.5%; P<0.01%) and indeterminate results (1.0% vs. 9.5%; P=0.02%). In the mixed exposure–risk–population, negative (NPA) and positive percent agreement (PPA) were 90.1% (1097/1217) and 92.1% (223/242), respectively. PPA increased with TB–exposure risk (up to 95.7% for high–risk participants), whereas NPA decreased (starting from 96.9% for low–risk participants). Regression analyses revealed that VIDAS TB–IGRA had a better fit with the risk–exposure gradient than the QFT‑Plus. Specificity in extremely low TB–exposure risk participants (n = 125) was high for both VIDAS TB–IGRA and QFT–Plus (97.6% vs. 95.2%; P=8.33%).
Conclusions: VIDAS TB–IGRA displayed greater sensitivity than QFT–Plus, had a lower indeterminate rate, correlated better with an exposure gradient, and was highly specific, suggesting that it is a potentially valuable tool for the diagnosis of LTBI.